Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua
Status:
Completed
Trial end date:
2017-10-30
Target enrollment:
Participant gender:
Summary
Allergic rhinitis (AR) is a common disease of nasal mucosa, affecting 10% to 40% of the
population globally. Allergen specific immunotherapy (AIT) is the only etiological treatment
available for AR.Traditionally, AIT is divided into subcutaneous immunotherapy (SCIT) and
sublingual immunotherapy (SLIT). Artemisia annua is one of the most important allergen that
is responsible for seasonal AR in China during July and October.
The trial is a randomized, double-blind, placebo-controlled, multicentred, phase III trial.
702 subjects with allergic rhinitis caused by Artemisia pollen were recruited and randomized
to the immunotherapy group and placebo group.